Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Dov Pharmaceutical, Inc - DOVP -- Ignore unavailable to you. Want to Upgrade?

To: michael_f_murphy who wrote (4)	4/17/2002 3:51:03 PM
From: tuck	Read Replies (1) \| Respond to of 172

>>By Michael Falbo Special to TheStreet.com Two companies from somewhat atypical industries are on the IPO calendar for next week. One represents biopharmaceuticals, which has been a struggling sector for IPOs this year, and the other should be the first REIT to price this year. On Tuesday, April 23, Dov Pharmaceuticals (proposed symbol DOVP:Nasdaq) plans to sell five million shares for $15 to $17 a share, raising an estimated $80 million. The Hackensack, N.J.-based biopharmaceutical company specializes in the development and commercialization of drugs to treat central nervous system, cardiovascular and urological disorders.<< snip Cheers, Tuck